ValuEngine Downgrades ProPhase Labs, Inc. (PRPH) to Sell

ValuEngine lowered shares of ProPhase Labs, Inc. (NASDAQ:PRPH) from a hold rating to a sell rating in a research report sent to investors on Thursday.

Shares of ProPhase Labs (NASDAQ PRPH) opened at 2.09 on Thursday. The stock has a 50 day moving average price of $2.21 and a 200-day moving average price of $2.08. The company has a market cap of $33.79 million, a price-to-earnings ratio of 0.87 and a beta of 0.02. ProPhase Labs has a 1-year low of $1.78 and a 1-year high of $2.45.

ProPhase Labs (NASDAQ:PRPH) last released its quarterly earnings results on Friday, August 11th. The company reported ($0.09) EPS for the quarter. The company had revenue of $1.91 million during the quarter. ProPhase Labs had a return on equity of 54.87% and a net margin of 270.98%.

TRADEMARK VIOLATION NOTICE: This report was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://ledgergazette.com/2017/10/09/valuengine-downgrades-prophase-labs-inc-prph-to-sell.html.

ProPhase Labs declared that its board has approved a stock buyback program on Tuesday, August 15th that authorizes the company to repurchase 4,000,000 shares. This repurchase authorization authorizes the company to buy shares of its stock through a tender offer. Stock repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

In other ProPhase Labs news, CFO Robert V. Cuddihy, Jr. sold 358,621 shares of the firm’s stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $2.30, for a total value of $824,828.30. Following the completion of the sale, the chief financial officer now owns 132,703 shares of the company’s stock, valued at $305,216.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Braden Michael Leonard sold 1,695,305 shares of the firm’s stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $2.30, for a total transaction of $3,899,201.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 2,423,255 shares of company stock valued at $5,573,487. 29.60% of the stock is currently owned by company insiders.

About ProPhase Labs

ProPhase Labs, Inc manufactures, markets and distributes a range of homeopathic and healthcare products. The Company is engaged in the research and development of over-the-counter (OTC) drugs and natural base health products, including supplements, personal care and cosmeceutical products. The Co

Shares of ProPhase Labs (NASDAQ PRPH) opened at 2.09 on Thursday. The stock has a 50 day moving average price of $2.21 and a 200-day moving average price of $2.08. The company has a market cap of $33.79 million, a price-to-earnings ratio of 0.87 and a beta of 0.02. ProPhase Labs has a 1-year low of $1.78 and a 1-year high of $2.45.

ProPhase Labs (NASDAQ:PRPH) last released its quarterly earnings results on Friday, August 11th. The company reported ($0.09) EPS for the quarter. The company had revenue of $1.91 million during the quarter. ProPhase Labs had a return on equity of 54.87% and a net margin of 270.98%.

TRADEMARK VIOLATION NOTICE: This report was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://ledgergazette.com/2017/10/09/valuengine-downgrades-prophase-labs-inc-prph-to-sell.html.

ProPhase Labs declared that its board has approved a stock buyback program on Tuesday, August 15th that authorizes the company to repurchase 4,000,000 shares. This repurchase authorization authorizes the company to buy shares of its stock through a tender offer. Stock repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

In other ProPhase Labs news, CFO Robert V. Cuddihy, Jr. sold 358,621 shares of the firm’s stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $2.30, for a total value of $824,828.30. Following the completion of the sale, the chief financial officer now owns 132,703 shares of the company’s stock, valued at $305,216.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Braden Michael Leonard sold 1,695,305 shares of the firm’s stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $2.30, for a total transaction of $3,899,201.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 2,423,255 shares of company stock valued at $5,573,487. 29.60% of the stock is currently owned by company insiders.

About ProPhase Labs

ProPhase Labs, Inc manufactures, markets and distributes a range of homeopathic and healthcare products. The Company is engaged in the research and development of over-the-counter (OTC) drugs and natural base health products, including supplements, personal care and cosmeceutical products. The Company’s products include TK Supplements and ORXx Complete.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for ProPhase Labs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply